Serum CA125 elevation is independently associated with serositis in SLE patients

Clinical and Experimental Rheumatology

Volumn 30, Issue 1, 2012, Pages 93-98

  Yang, Zaixing ^a   Liang, Yan ^a   Li, Chang ^a   Zhong, Renqian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CA125; Serositis; Systemic lupus erythematosus

Indexed keywords

CA 125 ANTIGEN;

AGED; AREA UNDER THE CURVE; ARTICLE; CHILD; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE DURATION; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; CA-125 ANTIGEN; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE PROTEINS; MIDDLE AGED; SEROSITIS;

EID: 84863762660     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. BAST RC JR, FEENEY M, LAZARUS H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-7.
2. MOORE RG, MACLAUGHLAN S. Current clinical use of biomarkers for epithelial ovarian cancer. Curr Opin Oncol 2010; 22: 492-7.
3. BASARAN A, TUNCER SZ. Ascites is the primary cause of cancer antigen-125 (CA-125) elevation in systemic lupus erythematosus (SLE) patients with nephritic syndrome. Medical Hypotheses 2007; 68: 197-201.
4. MIRALLES C, OREA M, ESPANA P et al. Cancer antigen-125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003; 10: 150-4.
5. ZUCKERMAN E, LANIR A, SABO E et al. Cancer antigen-125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999; 94: 1613-8.
6. ALAGOZ T, BULLER RE, BERMAN M et al. What is a normal CA125 level? Gynecol Oncol 1994; 53: 93-7.
7. BON GG, KENEMANS P, VERSTRAETEN R et al. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 1996; 174: 107-14.
8. FAIRHURST AM, WANDSTRAT AE, WAKELAND EK. Systemic lupus erythematosus: multiple immunologic phenotypes in a complex genetic disease. Adv Immunol 2006; 92: 1-69.
9. SZEKANECZ E, SZUCS G, SZEKANECZ Z et al. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: Associations with organ manifestations, immunolaboratory markers and disease activity indices. J Autoimmun 2008; 31: 372-6.
10. MIRET C, FONT J, MOLINA R et al. Lack of correlation between tumor markers (CA-125 and SCC) and systemic lupus erythematosus activity. Anticancer Res 1998; 18: 1341-4.
11. HOCHBERG MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
12. PAN HF, YE DQ, WANG Q et al. Clinical and laboratory profiles of systemic lupus erythematosus associated with Sjögren syndrome in China: a study of 542 patients. Clin Rheumatol 2008; 27: 339-43.
13. CLARKE A. Proposed modifications to 1982 ACR classification criteria for systemic lupus erythematosus: serositis criterion. Lupus 2004; 13: 855-6.
14. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG DH, AND THE COMMITTEE ON PROGNOSIS STUDIES IN SLE: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
15. TJALMA WA. Ascites, pleural effusion, and CA 125 elevation in an SLE patient, either a Tjalma syndrome or, due to the migrated Filshie clips, a pseudo-Meigs syndrome. Gynecol Oncol 2005; 97: 288-91.
16. KOH MS, SUNIL K, HOWE HS. Late onset systemic lupus erythematosus with elevated CA 125 and gastrointestinal ischaemia. Intern Med J 2002; 32: 117-8.
17. TAKEDA N, IHN H, TERAMOTO S. Markedly increased levels of IL-6 and CA125 in pleural fluid of an elderly person with overlap syndrome of systemic sclerosis and systemic lupus erythematosus. Age Ageing 2001; 30: 171.
18. YUCEL AE, CALGUNERI M, RUACAN S. False positive pleural biopsy and high CA125 levels in serum and pleural effusion in systemic lupus erythematosus. Clin Rheumatol 1996; 15: 197-9.
19. SZEKANECZ E, SANDOR Z, ANTAL-SZALMAS P et al. Increased production of the soluble tumor-associated antigens CA19-9, CA125 and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann N Y Acad Sci 2007; 1108: 359-71.
20. MONCAYO R, MONCAYO H. Serum levels of CA-125 are elevated in patients with active systemic lupus erythematosus. Obstet Gynecol 1991; 77: 932-4.
21. KIMURA K, EZOE K, YOKOZEKI H, KATAYAMA I, NISHIOKA K. Elevated serum CA-125 in progressive systemic sclerosis with pleural effusion. J Dermatol 1995; 22: 28-31.
22. CERVERA R, KHAMASHTA MA, FONT J et al. Morbidity and mortality in systemic lupus erythematosus during a five year period. A multicenter prospective study of 1,000 patients. European working party on systemic lupus erythematosus. Medicine (Baltimore). 1999; 78: 167-75.
23. RUMP A, MORIKAWA Y, TANAKA M et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004; 279: 9190-8.
24. SEELENMEYER C, WEGEHINGEL S, LECHNER J, NICKEL W. The cancer antigen CA125 represents a novel counter receptor for galectin- J Cell Sci 2003; 116: 1305-18.